Biogen Quote - 1BIIB

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Current Price

137.15

Bid

137.15

Offer

137.70

Volume

138.85 Day's Range 139.30

125.25 52 Week Range 220.70

Market Cap

20.075B

Previous Close

135.45

Open

138.85

Last Trade

137.15

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

Shares Outstanding

146,374,937

Dividend Yield

PE Ratio

12.79

Earnings Per Share (EPS)

11.15

Revenue

9.68B

Net Profit

1.63B

Sector

Biological Pds,ex Diagnstics

Industry

Biological Pds,ex Diagnstics

Website

www.biogen.com

Headquarters

Wilmington, Delaware, USA

Founded

Biogen Inc is listed in the Biological Pds,ex Diagnstics sector of the Italian Stock Exchange with ticker 1BIIB. The last closing price for Biogen was 135.45 €. Over the last year, Biogen shares have traded in a share price range of 125.25 € to 220.70 €.

Biogen currently has 146,374,937 shares in issue. The market capitalisation of Biogen is 19.83 € billion. Biogen has a price to earnings ratio (PE ratio) of 12.79.

Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments

Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare...

Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union

Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union TOKYO and CAMBRIDGE, Mass., Jan. 31, 2025 (GLOBE...

FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Once every four weeks maintenance...

FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA

FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA Applications are based on data from the DEVOTE study, which...

FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s...

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus...

Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease

Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease TOKYO and CAMBRIDGE, Mass., Nov...

Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference

Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD...

Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological Diseases

Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and...

Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer

Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer CAMBRIDGE, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	1.8	1.32988548208	135.35	139.3	133	106	136.26221591	DE
4	-1.65	-1.18876080692	138.8	141.35	125.25	83	132.82191476	DE
12	-11.45	-7.70524899058	148.6	149.65	125.25	74	138.74641183	DE
26	-48.8	-26.2436138747	185.95	185.95	125.25	61	147.48105552	DE
52	-63.85	-31.7661691542	201	220.7	125.25	49	163.385852	DE
156	-78.45	-36.3868274583	215.6	244.6	125.25	44	168.03083954	DE
260	-78.45	-36.3868274583	215.6	244.6	125.25	44	168.03083954	DE

1BIIB - Frequently Asked Questions (FAQ)

What is the current Biogen share price?

The current share price of Biogen is 137.15 €

How many Biogen shares are in issue?

Biogen has 146,374,937 shares in issue

What is the market cap of Biogen?

The market capitalisation of Biogen is EUR 19.83B

What is the 1 year trading range for Biogen share price?

Biogen has traded in the range of 125.25 € to 220.70 € during the past year

What is the PE ratio of Biogen?

The price to earnings ratio of Biogen is 12.79

What is the cash to sales ratio of Biogen?

The cash to sales ratio of Biogen is 2.16

What is the reporting currency for Biogen?

Biogen reports financial results in USD

What is the latest annual turnover for Biogen?

The latest annual turnover of Biogen is USD 9.68B

What is the latest annual profit for Biogen?

The latest annual profit of Biogen is USD 1.63B

What is the registered address of Biogen?

The registered address for Biogen is 3411 SILVERSIDE ROAD TATNALL, BUILDING #104, NEW CASTLE, WILMINGTON, DELAWARE, 19810

What is the Biogen website address?

The website address for Biogen is www.biogen.com

Which industry sector does Biogen operate in?

Biogen operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
1SPCEVirgin Galactic Holdings Inc	5.285 € (37.63%)	1.1k
WABTGAlfio Bardolla Training Group Spa	0.1018 € (29.68%)	500
WSOS26Sostravelcom SpA	0.0493 € (29.40%)	10k
1AMTAmerican Tower REIT	204.35 € (11.52%)	25
1AMSAmadeus IT Group SA	74.24 € (6.57%)	100
WIVN26iVision Tech SpA	0.33 € (-18.92%)	23.1k
WTFINTrevi Finanziaria Industriale Spa	0.61 € (-18.67%)	1.1k
WFTC26Finanzatech Spa	0.016 € (-17.95%)	1.25k
BIROEstrima Spa	0.368 € (-17.86%)	114.4k
1SRT3Sartorius AG	228.90 € (-17.19%)	17
TITTelecom Italia SpA	0.2555 € (-5.37%)	286.23M
ISPIntesa Sanpaolo Spa	4.659 € (-3.04%)	106.99M
SPMSaipem Spa	2.042 € (-5.20%)	71.48M
TITRTelecom Italia	0.289 € (-5.74%)	57.5M
STLAMStellantis NV	11.016 € (-10.64%)	53.54M